Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ADAPTIMMUNE THERAPEUTICS PLC

(ADAP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Adaptimmune Therapeutics : Company Presentation of Data at ASCO 2021 Annual Meeting- PDF

05/19/2021 | 05:20pm EDT

SPEARHEAD-1 Data at ASCO 2021 Annual Meeting May 19, 2021

Disclaimer

This presentation contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect" and other words of similar meaning. These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials; our ability to submit an IND and successfully advance our technology platform to improve the safety and effectiveness of our existing TCR therapeutic candidates; the rate and degree of market acceptance of T-cell therapy generally and of our TCR therapeutic candidates; government regulation and approval, including, but not limited to, the expected regulatory approval timelines for TCR therapeutic candidates; and our ability to protect our proprietary technology and enforce our intellectual property rights; amongst others. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 6, 2021 and our other SEC filings.

We urge you to consider these factors carefully in evaluating the forward-looking statements herein and you are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. The forward-looking statements contained in this presentation speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.

We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

2

Our vision and mission

Arming Cells.

Against Cancer.

For Good.

To transform the lives of people with cancer by designing and delivering cell therapies

3

5-year core value drivers: our "2-2-5-2" plan

Data from SPEARHEAD-1 will support our BLA filing next year for our first commercial MAGE-A4 targeted product

Two

Two

Five

Two

marketed

additional BLAs

autologous

allogeneic

SPEAR T-cell

for SPEAR T-cell

products in the

products entering

products targeting

products

clinic

the clinic

MAGE-A4

Synovial sarcoma

Additional indications

HiT

for MAGE-A4

Next-gen TILs

Esophageal and

EGJ cancers

targeted products

New targets

ADP-A2AFP

Broader HLA

coverage

  • SPEAR T-cell product targeting MAGE-A4
  • HiT mesothelin - partnered with Astellas

Integrated Cell Therapy Capabilities

Research | Preclinical | Translational | Clinical | CMC | Regulatory | Commercial

EGJ: esophagogastric junction cancer; HiT: HLA-independentT-cell

4 receptor (TCR); TIL: tumor infiltrating lymphocyte; CMC: chemistry, manufacturing, and controls

There is a large unmet medical need for people with synovial sarcoma

"Initial data from SPEARHEAD-1 indicate that afami-

"Amongst the limitations of using chemotherapy to

cel has the potential to offer people with synovial

treat synovial sarcoma is the need to always be on a

sarcoma a promising new treatment option where

therapy and to deal with the side effects that come

there is currently a great unmet medical need. As

from it. Chemo patients are not able to live a normal

clinicians, we want to be able to provide a treatment

life. What we're really looking for is a therapy where

regimen that can help offer a better quality of life."

once it's performed, it's durable and you don't need

-- Dr. Sandra P. D'Angelo of the

another one."

-- Dr. Brian Van Tine, Associate Professor of Medicine,

Memorial Sloan Kettering Cancer Center

Division of Oncology, Section of Medical Oncology,

Washington University School of Medicine

"After suffering from misdiagnosis or years long journey

to diagnosis, people living with synovial sarcoma struggle with limited, and often ineffective, treatment options. A treatment for synovial sarcoma patients that gives them more options, a better prognosis, and a better quality of life is long overdue."

-- Brandi Felser, CEO, Sarcoma Foundation of America

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Adaptimmune Therapeutics plc published this content on 19 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 May 2021 21:19:03 UTC.


© Publicnow 2021
All news about ADAPTIMMUNE THERAPEUTICS PLC
07/28Adaptimmune to Report Q2 2021 Financial Results and Business Update on Monday..
GL
07/22European ADRs Modestly Lower Thursday as Unilever Slides
MT
07/21European ADRs Move Sharply Higher in Wednesday Trading
MT
07/20European ADRs Up 0.5% Tuesday
MT
07/07European ADRs Nearly Flat Wednesday as Miners, Techs Gain
MT
07/02European ADRs Move Lower in Friday Trading
MT
06/30European ADRs Move Lower in Wednesday Trading
MT
06/23European ADRs Edge Higher in Wednesday Trading
MT
06/18European ADRs Down More Than 2% Friday as Banks, Drillers Drop
MT
06/16European ADRs Flat in Wednesday Morning Trading
MT
More news
Financials (USD)
Sales 2021 2,61 M - -
Net income 2021 -159 M - -
Net Debt 2021 - - -
P/E ratio 2021 -3,62x
Yield 2021 -
Capitalization 561 M 561 M -
Capi. / Sales 2021 215x
Capi. / Sales 2022 30,9x
Nbr of Employees 462
Free-Float 7,23%
Chart ADAPTIMMUNE THERAPEUTICS PLC
Duration : Period :
Adaptimmune Therapeutics plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADAPTIMMUNE THERAPEUTICS PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Last Close Price 3,61 $
Average target price 9,50 $
Spread / Average Target 163%
EPS Revisions
Managers and Directors
Adrian Rawcliffe Chief Executive Officer & Director
Gavin Wood Chief Financial Officer
David M. Mott Chairman
Elliot Norry Chief Medical Officer
William C. Bertrand Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
ADAPTIMMUNE THERAPEUTICS PLC-33.02%561
GILEAD SCIENCES, INC.20.25%87 579
BIONTECH SE283.45%75 497
WUXI APPTEC CO., LTD.38.94%70 844
REGENERON PHARMACEUTICALS21.38%60 387
VERTEX PHARMACEUTICALS-15.22%51 872